In fact, pharmacological agents likeanti-VEGF drugs have demonstrated to decrease the rate of vision loss, and insome cases improve the visual acuity of patients [208, 209].Nonetheless, anti-VEGF drugs could carry out detrimental changes in the retinalphysiology long-term, such as geographic atrophy, choroidal thinning, andinducing apoptosis in neurons and glia by disrupting VEGF-mediated survivalpathways. This evidence concerns the gene VEGFA and atrophic macular degeneration.